Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment
- PMID: 31008419
- PMCID: PMC6469713
- DOI: 10.1177/2470547019838971
Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment
Abstract
Background: In soldiers with posttraumatic stress disorder (PTSD), symptom provocation was found to induce increased connectivity within the salience network, as measured by functional magnetic resonance imaging (fMRI) and global brain connectivity with global signal regression (GBCr). However, it is unknown whether these GBCr disturbances would normalize following effective PTSD treatment.
Methods: 69 US Army soldiers with (n = 42) and without PTSD (n = 27) completed fMRI at rest and during symptom provocation using subject-specific script imagery. Then, participants with PTSD received 6 weeks (12 sessions) of group cognitive processing therapy (CPT) or present-centered therapy (PCT). At week 8, all participants repeated the fMRI scans. The primary analysis used a region-of-interest approach to determine the effect of treatment on salience GBCr. A secondary analysis was conducted to explore the pattern of GBCr alterations posttreatment in PTSD participants compared to controls.
Results: Over the treatment period, PCT significantly reduced salience GBCr (p = .02). Compared to controls, salience GBCr was high pretreatment (PCT, p = .01; CPT, p = .03) and normalized post-PCT (p = .53), but not post-CPT (p = .006). Whole-brain secondary analysis found high GBCr within the central executive network in PTSD participants compared to controls. Post hoc exploratory analyses showed significant increases in executive GBCr following CPT treatment (p = .01).
Conclusion: The results support previous models relating CPT to central executive network and enhanced cognitive control while unraveling a previously unknown neurobiological mechanism of PCT treatment, demonstrating treatment-specific reduction in salience connectivity during trauma recollection.
Keywords: PTSD; fMRI; functional connectivity; posttraumatic stress disorder; salience network; symptom provocation.
Conflict of interest statement
Conflicts of Interest CGA has served as a consultant and/or on advisory boards for FSV7, Genentech and Janssen, and editor of Chronic Stress for Sage Publications, Inc.; he has filed a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). JHK is a consultant for AbbVie, Inc., Amgen, Astellas Pharma Global Development, Inc., AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc., Neurovance, Inc., FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals, Inc., and Takeda Industries; is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., and Pfizer; is a stockholder in Biohaven Pharmaceuticals; holds stock options in Mnemosyne Pharmaceuticals, Inc.; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, US Patent No. 5,447,948 (issued September 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued July 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression. U.S. Application No. 14/197,767 (filed on March 5, 2014); US application or Patent Cooperation Treaty international application No. 14/306,382 (filed on June 17, 2014). Filed a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). All other co-authors declare no conflict of interest.
Figures



Similar articles
-
Salience Network Disruption in U.S. Army Soldiers With Posttraumatic Stress Disorder.Chronic Stress (Thousand Oaks). 2019 Jan-Dec;3:2470547019850467. doi: 10.1177/2470547019850467. Epub 2019 May 15. Chronic Stress (Thousand Oaks). 2019. PMID: 31131337 Free PMC article.
-
Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients.Chronic Stress (Thousand Oaks). 2018 Jan-Dec;2:2470547018796102. doi: 10.1177/2470547018796102. Epub 2018 Sep 21. Chronic Stress (Thousand Oaks). 2018. PMID: 30263977 Free PMC article.
-
ALTERED DEFAULT MODE NETWORK (DMN) RESTING STATE FUNCTIONAL CONNECTIVITY FOLLOWING A MINDFULNESS-BASED EXPOSURE THERAPY FOR POSTTRAUMATIC STRESS DISORDER (PTSD) IN COMBAT VETERANS OF AFGHANISTAN AND IRAQ.Depress Anxiety. 2016 Apr;33(4):289-99. doi: 10.1002/da.22481. Depress Anxiety. 2016. PMID: 27038410
-
Magnetic resonance imaging predictors of psychotherapy treatment response in post-traumatic stress disorder: A role for the salience network.Psychiatry Res. 2019 Jul;277:52-57. doi: 10.1016/j.psychres.2019.02.005. Epub 2019 Feb 2. Psychiatry Res. 2019. PMID: 30755338 Review.
-
A meta-analytic review of cognitive processing therapy for adults with posttraumatic stress disorder.Cogn Behav Ther. 2019 Jan;48(1):1-14. doi: 10.1080/16506073.2018.1522371. Epub 2018 Oct 18. Cogn Behav Ther. 2019. PMID: 30332919 Review.
Cited by
-
Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?Behav Brain Res. 2020 Jul 15;390:112628. doi: 10.1016/j.bbr.2020.112628. Epub 2020 May 11. Behav Brain Res. 2020. PMID: 32407817 Free PMC article. Review.
-
Measuring inter-individual differences in stress sensitivity during MR-guided prostate biopsy.Sci Rep. 2021 Jan 28;11(1):2454. doi: 10.1038/s41598-021-82199-z. Sci Rep. 2021. PMID: 33510379 Free PMC article. Clinical Trial.
-
Associations between resting-state functional connectivity and treatment response in a randomized clinical trial for posttraumatic stress disorder.Depress Anxiety. 2020 Oct;37(10):1037-1046. doi: 10.1002/da.23075. Epub 2020 Jul 15. Depress Anxiety. 2020. PMID: 32668087 Free PMC article. Clinical Trial.
-
Altered resting-state functional connectivity of the default mode and central executive networks following cognitive processing therapy for PTSD.Behav Brain Res. 2021 Jul 9;409:113312. doi: 10.1016/j.bbr.2021.113312. Epub 2021 Apr 22. Behav Brain Res. 2021. PMID: 33895228 Free PMC article.
-
Findings of PTSD-specific deficits in default mode network strength following a mild experimental stressor.NPP Digit Psychiatry Neurosci. 2024;2(1):9. doi: 10.1038/s44277-024-00011-y. Epub 2024 Jun 17. NPP Digit Psychiatry Neurosci. 2024. PMID: 38919723 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Medical